Eli Lilly And Verve Therapeutics Announces That The Tender Offer For All Outstanding Verve Shares, Priced At $10.50 Per Share In Cash Plus A Potential Additional $3.00 Via A Non-Tradable Contingent Value Right, Officially Expired At 12:01 A.M. Et On July 24, 2025. The Offer Was Not Extended.

Eli Lilly and Company (NYSE:LLY) and Verve Therapeutics, Inc. (NASDAQ:VERV) today announced that the tender offer to purchase all of the issued and outstanding shares ("Shares") of Verve's common stock in exchange for (i) $10.50 per Share, net to the stockholder in cash, without interest and less any applicable tax withholding, plus (ii) one non-tradable contingent value right ("CVR") per Share, which represents the contractual right to receive a contingent payment of up to $3.00 per CVR, net to the stockholder in cash, without interest and less any applicable tax withholding, upon the achievement of a certain specified milestone (the "Offer"), expired as scheduled at one minute past 11:59 p.m., Eastern time, on July 23, 2025 and was not extended (such date and time, the "Expiration Time").